Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)—a retrospective analysis from Indian Myositis Registry (MyoIN)
Clinical Rheumatology · 2024
DOI: 10.1007/s10067-024-07019-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Vineeta Shobha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, St. John's National Academy of Medical Sciences, Sarjapur Ro…. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Myositis, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Determine domain-based-outcomes and steroid-sparing efficacy of generic tofacitinib in IIM. METHODS: This is a multicenter retrospective study wherein clinical phenotype, autoantibody profile, prior immunosuppressives, and outcomes at 3, 6, and 12 months were retrieved for IIM patients prescribed tofacitinib. Overall clinical response was assessed as complete or partial remission as per physician judgment. Changes in cutaneous and calcinosis domain were recorded as per physician global assessment (PGA), lung domain as per medical research council (MRC) dyspnea scale, and muscle strength by Manual Muscle Testing-8 (MMT-8). RESULTS: Forty-two patients of IIM with mean age 38.7 ± 16 years; (76.2% (N = 32) women), median duration of illness 48 (19;88) months were included. Commonest indication for initiating tofacitinib was either for refractory or as steroid sparing for cutaneous domain (N = 25/42, 59.5%) followed by calcinosis (N = 16/42, 38%). Overall complete and/or partial remission was achieved in 23/37 (64.8%), 30/35 (85.7%), and 29/30 (96.6%) patients at 3, 6, and 12 months, respectively. At 12-month follow-up, there was a reduction in prednisolone dose, with absolute decrease from a daily dose of 17.5 mg (IQR 5;50) to 2.5 mg (IQR 0;5) (p < 0.001). Individual domain assessments revealed improvement in cutaneous domain [16/25 (64%)] and calcinosis [6/15 (40%)]. Adverse effects included herpes zoster (N = 2/42, 4.8%) and dyslipidemia (N = 4/42, 9.5%). CONCLUSIONS: Treatment with generic tofacitinib significantly reduces the daily dose of corticosteroids and is effective in cutaneous domain including calcinosis in IIM. KEY POINTS: • This multicenter retrospective study is the first real-world data from India, elucidating steroid sparing efficacy of generic tofacitinib in patients with inflammatory myositis. • Domain-based outcome assessment suggests good clinical improvement especially in cutaneous domain, even those with refractory disease. • Modest benefits were evident in calcinosis, but its effect on the muscle and pulmonary domain appears limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, St. John's National Academy of Medical Sciences, Sarjapur Road, Bengaluru, 560034, India. vineeta.s@stjohns.in.
- Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, St. John's National Academy of Medical Sciences, Sarjapur Road, Bengaluru, 560034, India.
- Rheumatic Disease Clinic, Mumbai, India.
- Star Clinics, Ahmedabad, Gujarat, India.
- Niramaya Health Care, Jaipur, Rajasthan, India.
- Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India.
Zitieren
APA
Shobha, V., Kodali, R., Amin, S. N., Srivastava, P., Sharma, B., Goel, R., Ganapati, A., Dhote, S., Janardana, R., Rajasekhar, L., & Misra, R. (2024). Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)—a retrospective analysis from Indian Myositis Registry (MyoIN). Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07019-x
Vancouver
Shobha V, Kodali R, Amin SN, Srivastava P, Sharma B, Goel R, et al. Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)—a retrospective analysis from Indian Myositis Registry (MyoIN). Clinical Rheumatology. 2024. doi:10.1007/s10067-024-07019-x
BibTeX
@article{Shobha2024,
author = {Shobha, Vineeta and Kodali, RamyaSri and Amin, Sanjiv N and Srivastava, Puja and Sharma, Banwari and Goel, Ruchika and Ganapati, Arvind and Dhote, Sachin and Janardana, Ramya and Rajasekhar, Liza and Misra, Ramnath},
title = {Effectiveness of generic tofacitinib in idiopathic inflammatory myositis (IIM)—a retrospective analysis from Indian Myositis Registry (MyoIN)},
journal = {Clinical Rheumatology},
year = {2024},
doi = {10.1007/s10067-024-07019-x}
}
EUVIMED